Inverness and P&G
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble has signed a "non-binding letter of intent" with Inverness Medical Innovations to "form a joint venture to develop and market consumer diagnostic products," the firms announce July 18. The planning required to reach a final agreement will "take several months," they add. The agreement will combine Inverness' experience developing and manufacturing consumer diagnostics with P&G's knowledge of marketing consumer healthcare products, Waltham, Mass.-based Inverness states. Current consumer diagnostic offerings by Inverness include several pregnancy, ovulation and fertility tests under the Clearblue, FactPlus, Accu-Clear, Persona and Clearplan brands...
You may also be interested in...
P&G Moves Into Consumer Diagnostics With Inverness Joint Venture
Procter & Gamble enters the consumer diagnostic products business with an agreement to form a 50/50 joint venture with Waltham, Mass.-based Inverness Medical Innovations
Trinity Biotech’s OTC HIV tests?
Inverness Medical Innovations grants Trinity Biotech a royalty bearing license to its lateral flow patents for all diagnostic uses except women's health and cardiology, including an OTC license for Trinity's Unigold HIV products, Trinity announces Aug. 8. Procter & Gamble signed a "non-binding letter of intent" with Inverness to develop and market consumer diagnostic products in July 1("The Tan Sheet" July 24, 2006, In Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.